Mepivacaína B. Braun (Mepivacaine Hydrochloride)

Mepivacaine blocks voltage‑gated sodium channels on neuronal membranes, preventing the rapid influx of sodium ions needed for depolarization. This stops the initiation and propagation of nerve impulses, producing a reversible loss of sensation in the region where it is administered.

The specific dose of Mepivacaína B. Braun is determined by the prescribing clinician based on the procedure, patient age, weight, and health status. Healthcare professionals calculate the appropriate volume and concentration to achieve effective anesthesia while minimizing risk.

Safety data for mepivacaine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Use is only considered when the potential benefit justifies any potential risk, and it should be administered under close medical supervision.

To request Mepivacaína B. Braun, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both mepivacaine and lidocaine are amide‑type local anesthetics, but mepivacaine has a slightly longer duration of action and a lower pKa, which may result in a faster onset. Lidocaine is often chosen for its well‑established safety profile, while mepivacaine may be preferred when a longer block is desired without adding epinephrine.

Mepivacaína B. Braun should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the solution from direct sunlight, moisture and extreme temperature fluctuations to maintain sterility and potency.

The product is supplied as a sterile solution for injection. It is administered by a qualified healthcare professional via epidural, perineural or retrobulbar routes, using aseptic technique and appropriate needle or catheter size for the intended block.

Serious risks include allergic reactions such as anaphylaxis, cardiovascular toxicity like arrhythmias or severe hypotension, and central nervous system toxicity leading to seizures or respiratory depression. Prompt recognition and supportive management are essential if these events occur.

Patients with a known hypersensitivity to mepivacaine or other amide‑type local anesthetics, those with severe cardiac conduction disorders, or individuals with uncontrolled epilepsy should avoid this medication. Contraindications should be confirmed by the prescribing clinician before use.